Govan Vandana A, Rybicki Edward P, Williamson Anna-Lise
Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa.
Virol J. 2008 Mar 20;5:45. doi: 10.1186/1743-422X-5-45.
There is overwhelming evidence that persistent infection with high-risk human papillomaviruses (HR-HPV) is the main risk factor for invasive cancer of the cervix. Due to this global public health burden, two prophylactic HPV L1 virus-like particles (VLP) vaccines have been developed. While these vaccines have demonstrated excellent type-specific prevention of infection by the homologous vaccine types (high and low risk HPV types), no data have been reported on the therapeutic effects in people already infected with the low-risk HPV type. In this study we explored whether regression of CRPV-induced papillomas could be achieved following immunisation of out-bred New Zealand White rabbits with CRPV VLPs. Rabbits immunised with CRPV VLPs had papillomas that were significantly smaller compared to the negative control rabbit group (P < or = 0.05). This data demonstrates the therapeutic potential of PV VLPs in a well-understood animal model with potential important implications for human therapeutic vaccination for low-risk HPVs.
有压倒性的证据表明，高危型人乳头瘤病毒（HR-HPV）的持续感染是宫颈癌侵袭性癌症的主要危险因素。鉴于这一全球公共卫生负担，已研发出两种预防性HPV L1病毒样颗粒（VLP）疫苗。虽然这些疫苗已证明对同源疫苗类型（高危和低危HPV类型）的感染具有出色的型特异性预防作用，但尚无关于已感染低危HPV类型人群治疗效果的数据报道。在本研究中，我们探讨了用棉尾兔乳头瘤病毒（CRPV）VLP免疫远交系新西兰白兔后，CRPV诱导的乳头瘤是否会消退。与阴性对照兔组相比，用CRPV VLP免疫的兔子的乳头瘤明显更小（P≤0.05）。该数据证明了PV VLP在一个易于理解的动物模型中的治疗潜力，这对低危HPV的人类治疗性疫苗接种可能具有重要意义。
